NCT06001788 2026-04-14Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid LeukemiaKura Oncology, Inc.Phase 1 Recruiting171 enrolled
NCT03911388 2026-04-13HSV G207 in Children With Recurrent or Refractory Cerebellar Brain TumorsM.D. Anderson Cancer CenterPhase 1 Recruiting24 enrolled
NCT04572451 2025-08-01Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and MelanomaUniversity of PittsburghPhase 1 Recruiting50 enrolled
NCT05963217 2025-07-02Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLLUniversity Health Network, TorontoPhase 1 Recruiting19 enrolled
NCT06271252 2024-08-02A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL StudyOriCell Therapeutics Co., Ltd.Phase 1 Recruiting81 enrolled